Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 45

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 45
---
ly owned by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. Adjuvant

<div align='center'>25</div>

Capital GP, L.P. has shared voting and shared dispositive power over the shares held by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. Mr. Aziz is a limited partner of Adjuvant Capital GP, L.P. and shares voting and dispositive power over the shares held by Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. Mr. Aziz, however, disclaims beneficial ownership of such shares of common stock, except to the extent of any pecuniary interest therein. The address of the persons and entities listed above is 500 Fifth Avenue, Suite 5120, New York, New York 10110.

Consists of (i) 1,065,766 shares of common stock held by the Easom Living Trust dated August 21, 2019 of which Mr. Easom is a trustee, (ii) 97,058 shares of common stock held by the C. Easom Irrevocable Trust dated October 8, 2021 of which Mr. Easom is a trustee, (iii) 97,058 shares of common stock held by the Jude Easom Irrevocable Trust dated October 8, 2021 of which Mr. Easom is a trustee, (iv) 26,880 shares of common stock held by Mr. Easom and (v) 669,773 shares of common stock that may be acquired by Mr. Easom pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 15,002 shares of common stock and (ii) 266,634 shares of common stock that may be acquired by Ms. Day pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 27,335 shares of common stock and (ii) 126,295 shares of common stock that may be acquired by Mr. Eizen pursuant to the exercise of stock options within 60 days of March 24, 2025.

Consists of (i) 8,972 share of common stock, (ii)